Literature DB >> 14965793

Interferon-gamma in alopecia areata.

Ercan Arca1, Ugur Muşabak, Ahmet Akar, A Hakan Erbil, H Bülent Taştan.   

Abstract

Alopecia areata is a common type of hair loss. In clinical practice most patients will present with reversible patchy hair loss whereas others may develop complete baldness. Although the etiopathogenesis of alopecia areata is poorly understood, evidence is accumulating that it can be regarded as a T-cell mediated tissue-restricted autoimmune disease of the hair follicle, especially expressing the T-helper-type 1 cytokines interleukin-1beta, interleukin-2, and interferon-gamma. The aim of the study was to compare the serum levels of interferon-gamma in patients with alopecia areata and the control group and also to investigate the difference between the localized form of the disease with the extensive forms like alopecia totalis (AT) and alopecia universalis (AU). Forty patients with alopecia areata and 20 healthy controls were enrolled in the study. Nineteen patients had localized AA (LAA) and twenty-one patients had AT, AU or AT/AU. The serum levels of interferon-y were measured using enzyme immunoassay techniques. The mean serum IFN-gamma level in AA patients (n = 40) was 14.25 +/- 8.76 pg/mL (mean +/- SD), whereas that of LAA (n = 19) or extensive (AT, AU or AT/AU) (n = 21) was 13.45 +/- 6.75 pg/mL or 14.98 +/- 10.37 pg/mL, respectively. The mean serum IFN-gamma level in controls was 9.95 +/- 2.6 pg/mL. Serum levels of IFN-gamma in patients with AA were significantly higher than those in controls (p < 0.05). Significant difference was observed in serum levels of IFN-y between patients with LAA and control group (p < 0.05). Serum levels of IFN-gamma in patients with AT, AU or AT/AU were significantly higher than those in controls (p < 0.05). There was no significant difference in levels of IFN-gamma between patients with LAA and extensive group (p > 0. 05). We conclude that the elevated serum levels of IFN-gamma may reflect the inflammatory symptoms in AA, especially in the extensive form and that control of IFN-gamma production may be important to management of this disease. And also the measurement of serum IFN-gamma in patients with AA may be useful in discriminating those likely to progress to AU from the remaining LAA, or as a prognostic indicator. Copyright John Libbey Eurotext 2003.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14965793

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  13 in total

1.  Review.

Authors:  Gloria Taliani; Elisa Biliotti
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-08

2.  Serum cytokine levels and anxiety and depression rates in patients with alopecia areata.

Authors:  Arzu Ataseven; Yunus Saral; Ahmet Godekmerdan
Journal:  Eurasian J Med       Date:  2011-08

Review 3.  Cytokines and other mediators in alopecia areata.

Authors:  Stamatis Gregoriou; Dafni Papafragkaki; George Kontochristopoulos; Eustathios Rallis; Dimitrios Kalogeromitros; Dimitris Rigopoulos
Journal:  Mediators Inflamm       Date:  2010-03-11       Impact factor: 4.711

Review 4.  Baricitinib: From Rheumatoid Arthritis to COVID-19.

Authors:  Sara Assadiasl; Yousef Fatahi; Banafsheh Mosharmovahed; Bahareh Mohebbi; Mohammad Hossein Nicknam
Journal:  J Clin Pharmacol       Date:  2021-06-12       Impact factor: 2.860

Review 5.  Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata.

Authors:  Taisuke Ito
Journal:  Clin Dev Immunol       Date:  2013-09-18

6.  The Contributory Roles of Th17 Lymphocyte and Cytotoxic T Lymphocyte at the Hair Bulge Region as Well as the Hair Bulb Area in the Chronic Alopecia Areata Patients.

Authors:  Jin-Woo Hong; Chae-Young Lee; Seung-Min Ha; Seung-Hwan Choi; Tae-Hoon Kim; Ki-Hoon Song; Ki-Ho Kim
Journal:  Ann Dermatol       Date:  2017-03-24       Impact factor: 1.444

7.  Serum concentrations of selected proinflammatory cytokines in children with alopecia areata.

Authors:  Katarzyna Tabara; Magdalena Kozłowska; Anna Jędrowiak; Wojciech Bienias; Andrzej Kaszuba
Journal:  Postepy Dermatol Alergol       Date:  2019-02-22       Impact factor: 1.837

Review 8.  Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update.

Authors:  Thipprapai Mahasaksiri; Chaninan Kositkuljorn; Tanaporn Anuntrangsee; Poonkiat Suchonwanit
Journal:  Drug Des Devel Ther       Date:  2021-03-23       Impact factor: 4.162

9.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

10.  Do Prolactin and its Receptor Play a Role in Alopecia Areata?

Authors:  Samar M El Tahlawi; Nermeen H El Eishi; Rima K Kahhal; Rehab A Hegazy; Ghada M El Hanafy; Rania M Abdel Hay; Olfat G Shaker
Journal:  Indian J Dermatol       Date:  2018 May-Jun       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.